The UK's most valuable company remains a cornerstone for healthcare exposure, with 20 out of 24 analysts rating it a "Buy" due to a strong oncology pipeline and projected EPS growth of 60% by 2028.
A major success story, Rolls-Royce has reinstated regular dividends and announced a multi-billion-pound share buyback program (2026–2028), positioning itself to power AI data centers with its nuclear reactor technology. ftse stocks to buy
Analysts are currently highlighting a mix of defensive giants and high-growth turnaround stories: The UK's most valuable company remains a cornerstone
A classic defensive choice yielding 5.5% , supported by resilient cash flow and a "Buy" rating from platforms like TipRanks . Growth Potential in the FTSE 250 ftse stocks to buy